Nagelafwijkingen door geneesmiddelen
Publisher
Bohn Stafleu van Loghum
Reference9 articles.
1. Toonstra J, de Groot AC. Voeten en kanker. Houten: Bohn Stafleu van Loghum: 2016
2. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies. Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015;72:203–218
3. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies. Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 2015;72:221–236
4. Baran R, Fouilloux B, Robert C. Nail abnormalities in oncology practice. In: Lacouture ME, red. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. Hoboken, NJ, USA: John Wiley & Sons: 2014: pp. 115-121
5. Peuvrel L, Dréno B. Dermatological toxicity associated with targeted therapies in cancer: optimal management. Am J Clin Dermatol 2014;15:425–444